Medicalgorithmics S.A.

Medicalgorithmics S.A.

MDG.WA
Medicalgorithmics S.A.PL flagWarsaw Stock Exchange
27.40
PLN
-0.35
- -
272.71MMarket Cap
Medicalgorithmics S.A.
MDG.WA
(Warsaw Stock Exchange)

Recent

price

27.40

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
47.02
2.33
3.81
4.59
8.6
14.27
35.46
56.38
55.28
48.2
27
10.63
11
4.33
2.41
2.7
Revenue per Share
21.86
1.21
2.58
3.18
4.2
4.03
11.12
7.08
4
1.19
-3.12
-39.73
-2.08
-0.06
-1.62
-1.55
Basic EPS, GAAP
19.11
0.33
1.92
1.56
-2.33
4.24
7.48
-2.56
10.48
1.32
-0.96
-1.42
-1.06
-1.12
-2.32
-0.5
Free Cash Flow per Basic Share
- -
- -
- -
1.1
1.35
1.6
1.77
3.21
1.42
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
32.39
0.26
2.7
3.28
4.3
4.13
11.22
16.3
20.07
21.26
18.44
-22.93
-20.31
-11.69
-13.31
-14.41
Book Value per Share
22.84
4.11
25.23
22.14
23.57
25.58
-6.22
1.89
5.63
4.16
1.35
-0.7
5.4
2
-0.13
-1.86
Tangible Book Value per Share
- -
2
3
3
3
3
4
4
4
4
4
5
6
10
10
10
Basic Weighted Avg Shares
4
6
11
16
30
49
128
203
199
174
112
48
63
43
24
27
Sales/Revenue/Turnover
51.53
53.19
64.51
63.74
46.75
43.78
36.31
20.46
12.79
0.2
-30.79
25.09
25.59
1.28
-67.88
-39.69
Operating Margin (%)
- -
- -
- -
- -
1
2
5
12
12
19
16
18
4
2
4
4
Depreciation Expense
2
3
7
11
15
14
40
26
14
4
-13
-181
-12
-1
-16
-15
Net Income, GAAP
6.51
11.7
19.19
19.3
19.3
19.46
6.8
8.03
12.17
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
46.5
51.78
67.62
69.27
48.89
28.23
31.35
12.56
7.23
2.46
-11.56
-373.61
-18.91
-1.34
-67
-57.39
Profit Margin (%)
1
7
64
46
42
52
16
43
17
8
4
-4
46
31
13
9
Working Capital
- -
- -
- -
- -
- -
- -
50
50
8
24
12
8
- -
- -
3
16
LT Debt
3
12
74
81
91
99
215
204
231
225
207
47
95
93
77
66
Total Equity
- -
36.35
13.27
10.4
13.03
18.28
23.07
14.21
8
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
173.13
178.32
114.45
111.24
95.59
53.93
14.57
7.82
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
172.87
176.43
114.64
111.36
95.56
146.54
51.46
21.98
5.74
-16.89
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Mar'25
Jun'25
Sep'25
ST Debt
3
- -
- -
LT Borrowings
5
11
16
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
10
10
Market Capitalization
260
248
394

Working Capital

FRC

in mil. unless spec.
Mar'25
Jun'25
Sep'25
Total Current Assets
20
18
17
Cash, Cash Equivalents & STI
6
3
3
Accounts Receivable, Net
7
8
7
Inventories
8
7
7
Total Current Liabilities
11
7
8
Payables & Accruals
- -
- -
- -
ST Debt
3
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.74%
-0.79%
-16.62%
Free Cash Flow
-86.39%
13.02%
106.94%
Net Income, GAAP
342.36%
677.99%
2,682.18%
Sales/Revenue/Turnover
13.12%
-27.67%
-44.31%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7
6
5
6
24
2025
7
7
7
10
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.4
-0.53
-0.21
- -
-1.62
2025
-0.42
-0.25
-0.41
-0.22
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Business
Medicalgorithmics S.A. delivers advanced cardiac diagnostic and monitoring solutions across global markets, including Poland, the United States, and numerous other countries. The company’s flagship offering, PocketECG, is a comprehensive system designed for arrhythmia detection, providing full-disclosure ECG data, in-depth analysis, and detailed diagnostic reporting, functioning seamlessly as a long-term Holter, event monitor, and mobile cardiac telemetry device. Medicalgorithmics also pioneers AI-driven technologies like DeepRhythmAI (DRAI), an FDA-approved algorithm for rapid and precise heart rhythm analysis, and the cloud-based DeepRhythm Platform (DRP), which integrates with diverse hardware for enhanced ECG interpretation. Complementing these, Kardiobeat.ai offers extended Holter monitoring with AI diagnostics, while VCAST provides an innovative AI-based virtual cardiac stress test for non-invasive coronary artery disease assessment. Since its establishment in 2005, and headquartered in Warsaw, Poland, the firm has strategically pivoted to emphasize high-margin software licensing and AI algorithm integration with third-party systems, expanding its service revenue and global client base, including significant growth in the US market and new entries into regions like the Middle East.